A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers. Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence of IRAEs ranging from 2% to 5%. Most of the initial data related to kidney IRAEs have focused on acute interstitial nephr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Kidney Int Rep
Autors principals: Kitchlu, Abhijat, Jhaveri, Kenar D., Wadhwani, Shikha, Deshpande, Priya, Harel, Ziv, Kishibe, Teruko, Henriksen, Kammi, Wanchoo, Rimda
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783581/
https://ncbi.nlm.nih.gov/pubmed/33426386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2020.10.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars